“…Sensitive and accurate biosensing systems for these biomarkers can not only significantly aid in the early diagnosis and clinical management of AIDs but also help to establish therapeutic strategies [ 4 ]. Biosensors for the detection of autoantibodies specific to AIDs, including antiphospholipid syndrome (APS) [ 91 , 92 , 93 , 94 ], rheumatoid arthritis (RA) [ 95 , 96 , 97 , 98 , 99 ], systemic lupus erythematosus (SLE) [ 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 ], multiple sclerosis (MS) [ 108 , 109 , 110 , 111 ], and celiac disease (CD) [ 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ], are now constructed based on diverse techniques with many advantages, including high sensitivity and easy operation.…”